Institute News
Most Popular
MacTel SAFE Study
March 6, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database. LMRI is conducting the SAFE study (Phase 2a Study of the Effect of Serine Supplementation and Fenofibrate Treatment on Serum...
The Latest MacTel Research: What does it mean for patients?
Scientists at the Lowy Medical Research Institute and their collaborators recently published an article describing a role for serine and toxic lipids in macular telangiectasia type 2. The article, “Serine and Lipid Metabolism in Macular Disease and...
CNTF Clinical Trials: COVID-19 Update
March 24, 2020 The rapid spread of COVID-19 has disrupted many standard clinical operations, including the LMRI/Neurotech Phase 1, 2, and 3 clinical trials testing CNTF in MacTel. If you have questions regarding upcoming appointments or other study-...
Free community webinar about MacTel
November 14, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database. Neurotech has partnered with Prevent Blindness to sponsor an online event with a focus on MacTel Type 2. This free webinar...
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)
LMRI would like to share the following press release from Neurotech Pharmaceuticals about the BLA for NT-501 as a treatement for MacTel: Cumberland, R.I., November 8, 2024 (BUSINESS WIRE) – Neurotech Pharmaceuticals, Inc., an innovator in sustained...